Clinical effects and tolerability of high-dose, high-frequency recombinant interferon beta-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence.
about
When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohoRt evaluation) Noninterventional Study Protocol.Subcutaneous Interferon β-1a Administration by Electronic Auto-injector is Associated with High Adherence in Patients with Relapsing Remitting Multiple Sclerosis in a Real-life Study.Biologic therapies in non-rheumatic diseases: lessons for rheumatologists?Interleukin-4 induced 1 (IL4I1) promotes central nervous system remyelination.
P2860
Clinical effects and tolerability of high-dose, high-frequency recombinant interferon beta-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical effects and tolerabil ...... y through long-term adherence.
@en
Clinical effects and tolerabil ...... y through long-term adherence.
@nl
type
label
Clinical effects and tolerabil ...... y through long-term adherence.
@en
Clinical effects and tolerabil ...... y through long-term adherence.
@nl
prefLabel
Clinical effects and tolerabil ...... y through long-term adherence.
@en
Clinical effects and tolerabil ...... y through long-term adherence.
@nl
P2860
P1476
Clinical effects and tolerabil ...... y through long-term adherence.
@en
P2093
Alexey N Boyko
P2860
P304
P356
10.1517/14712591003702361
P407
P577
2010-04-01T00:00:00Z